VanEck Associates
AVNS

VanEck Associates’s Avanos Medical AVNS Stock Holding History

VanEck Associates’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,110
Closed -$64K – 795
2018
Q2 		$64K Hold
1,110
– – ﹤0.01% 758
2018
Q1 		$51K Buy
1,110
+39
+4% +$1.85K ﹤0.01% 681
2017
Q4 		$49K Sell
1,071
-279
-21% -$12.8K ﹤0.01% 690
2017
Q3 		$61K Sell
1,350
-131
-9% -$5.59K ﹤0.01% 700
2017
Q2 		$58K Sell
1,481
-29
-2% -$1.1K ﹤0.01% 674
2017
Q1 		$58K Buy
1,510
+642
+74% +$25K ﹤0.01% 814
2016
Q4 		$32K Sell
868
-228
-21% -$8.15K ﹤0.01% 838
2016
Q3 		$38K Buy
1,096
+58
+6% +$2.03K ﹤0.01% 793
2016
Q2 		$34K Sell
1,038
-59
-5% -$1.81K ﹤0.01% 780
2016
Q1 		$32K Buy
1,097
+243
+28% +$6.47K ﹤0.01% 747
2015
Q4 		$29K Sell
854
-142
-14% -$4.42K ﹤0.01% 720
2015
Q3 		$28K Buy
996
+388
+64% +$13.5K ﹤0.01% 758
2015
Q2 		$25K Buy
+608
New +$27.3K ﹤0.01% 769

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

VanEck Associates's AVNS Position: Q3 2018 in Review

VanEck Associates sold out of Avanos Medical (AVNS) in Q3 2018, closing a stake of 1,110 shares — an estimated $64K sold.

VanEck Associates first reported a position in AVNS in Q2 2015 and held it in 13 quarters. The position peaked at $64K in Q2 2018. 387 funds tracked by Wall St. Rank hold AVNS as of Q3 2018.

  • VanEck Associates reported no remaining Avanos Medical position as of Q3 2018 after selling out during the quarter.
  • VanEck Associates sold 1,110 Avanos Medical shares in Q3 2018, an estimated $64K.
  • VanEck Associates first reported a position in Avanos Medical in Q2 2015 and held it in 13 quarters.
  • VanEck Associates's Avanos Medical position peaked at $64K in Q2 2018.
  • 387 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2018.

Based on VanEck Associates's 13F filing for Q3 2018, filed 13 Nov 2018.